Synergy Pharmaceuticals Inc (NASDAQ:SGYP)a biopharmaceutical firm focused on the commercialization and development of novel gastrointestinal therapies reported that the company has appointed Gary Sender as Executive VP and Chief Financial Officer. He will be responsible for directing Synergy’s operations and financial strategy, supporting all functions of the company.
The management view
Gary S. Jacob, the CEO and Chairman of Synergy, said that Mr. Sender is a strong leader whose extensive experience in larger and small specialty pharmaceutical firms uniquely qualifies him to build and lead company’s financial operations as they move into a transformative period of company’s history.
Having earlier managed financial planning and analysis and strategic growth measures of Shire’s Global Commercial operations, Sender has a detailed understanding of the thrilling prospects from which Synergy is set to benefit. The CEO added that he is confident Mr. Sender can add significant value as Synergy prepare to enter a dynamic and growing GI market.
Expressing his views on new role, Mr. Sender said that he was immediately attracted to the energy and excitement around Synergy. The company is entering into a period of opportunity and growth with expected approval of regulatory filings in 2016 and the commercial launch of plecanatide intended for 2017. He look forward to working together with the team to successfully implement on these objectives and continue to drive considerable shareholder return.
Sender has morethan twenty-five years of financial leadership experience in the biopharmaceutical and pharmaceutical industries, recently at Shire plc. Prior to this, Sender served as Senior VP, Finance backing its Specialty Pharmaceuticals operations and subsequently its Global Commercial operations. At Shire, he was accountable for financial management and support of commercial segments of company’s Specialty Pharmaceutical and Rare Disease operations, including the Gastroenterology Business segment, with a focus on resource allocation, business cases, M&A and financial forecasting.